Stay updated with breaking news from Allo Hsct. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Among the 10 patients in the retrospective analysis, the median overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) was 21 months.
Focus on methods for preventing graft-versus-host disease (GvHD) following allo-HSCT, such as pharmacologic immune suppression and stem cell graft manipulation techniques.
Analyze risks and complications associated with allo-HSCT, including graft-versus-host disease, infections, relapse, and regimen-related toxicities.
This presentation will detail the supportive therapies and interventions provided to patients before, during, and after undergoing allo-HSCT. The speaker will also discuss management of treatment side effects and comorbidities to optimize patient outcomes.
Delve into the pre-transplant conditioning regimens such as chemotherapy and radiation used to prepare and immunosuppress patients to prevent graft rejection prior to allogeneic hematopoietic stem cell transplantation.